318 related articles for article (PubMed ID: 16318402)
21. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies.
Meece J
Curr Med Res Opin; 2007 Apr; 23(4):933-44. PubMed ID: 17407650
[TBL] [Abstract][Full Text] [Related]
22. Incretins and Their Endocrine and Metabolic Functions.
Seufert J
Endocr Dev; 2017; 32():38-48. PubMed ID: 28873383
[TBL] [Abstract][Full Text] [Related]
23. [The incretin effect: a new therapeutic target in type 2 diabetes].
Féry F
Rev Med Brux; 2007 Sep; 28(4):329-35. PubMed ID: 17958029
[TBL] [Abstract][Full Text] [Related]
24. GLP-1: physiological effects and potential therapeutic applications.
Aaboe K; Krarup T; Madsbad S; Holst JJ
Diabetes Obes Metab; 2008 Nov; 10(11):994-1003. PubMed ID: 18435775
[TBL] [Abstract][Full Text] [Related]
25. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
26. [New therapeutic approach in patients with type 2 diabetes based on glucagon-like peptide 1 (GLP-1) and gastric inhibitory peptide (GIP)].
Kluz J; Adamiec R
Postepy Hig Med Dosw (Online); 2006; 60():15-23. PubMed ID: 16407790
[TBL] [Abstract][Full Text] [Related]
27. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
28. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes.
Nauck MA; Meier JJ
Regul Pept; 2005 Jun; 128(2):135-48. PubMed ID: 15780433
[TBL] [Abstract][Full Text] [Related]
29. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
30. Incretin-based therapy of type 2 diabetes mellitus.
Knop FK; Vilsbøll T; Holst JJ
Curr Protein Pept Sci; 2009 Feb; 10(1):46-55. PubMed ID: 19275672
[TBL] [Abstract][Full Text] [Related]
31. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
Creutzfeldt W
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
[TBL] [Abstract][Full Text] [Related]
32. Potential New Approaches to Modifying Intestinal GLP-1 Secretion in Patients with Type 2 Diabetes Mellitus : Focus on Bile Acid Sequestrants.
Holst JJ; McGill MA
Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 27933595
[TBL] [Abstract][Full Text] [Related]
33. [Incretin enhancers, incretin mimetics: from therapeutic concept to clinical application].
Winkler G
Orv Hetil; 2007 Apr; 148(13):579-87. PubMed ID: 17383951
[TBL] [Abstract][Full Text] [Related]
34. A Protein Preload Enhances the Glucose-Lowering Efficacy of Vildagliptin in Type 2 Diabetes.
Wu T; Little TJ; Bound MJ; Borg M; Zhang X; Deacon CF; Horowitz M; Jones KL; Rayner CK
Diabetes Care; 2016 Apr; 39(4):511-7. PubMed ID: 26786576
[TBL] [Abstract][Full Text] [Related]
35. Very short-term effects of the dipeptidyl peptidase-4 inhibitor sitagliptin on the secretion of insulin, glucagon, and incretin hormones in Japanese patients with type 2 diabetes mellitus: analysis of meal tolerance test data.
Murai K; Katsuno T; Miyagawa J; Matsuo T; Ochi F; Tokuda M; Kusunoki Y; Miuchi M; Namba M
Drugs R D; 2014 Dec; 14(4):301-8. PubMed ID: 25420579
[TBL] [Abstract][Full Text] [Related]
36. Glucagon-like peptide 1 based therapy for type 2 diabetes.
Yu BS; Wang AR
World J Pediatr; 2008 Feb; 4(1):8-13. PubMed ID: 18402245
[TBL] [Abstract][Full Text] [Related]
37. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
38. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
39. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
40. Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats.
Schwasinger-Schmidt T; Robbins DC; Williams SJ; Novikova L; Stehno-Bittel L
Pharmacol Res; 2013 Oct; 76():58-66. PubMed ID: 23891763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]